ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Chicago, IL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Skin Diseases
Food Hypersensitivity
Hypersensitivity
Psoriasis
Allergic Rhinitis

Eczema trials near Chicago, IL, USA:

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial (DISCOVER)

The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema...

Active, not recruiting
Atopic Eczema
Moderate-to-Severe Atopic Dermatitis
Other: Topical emollient (moisturizer)
Drug: dupilumab

Phase 4

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Chicago, Illinois, United States and 29 other locations

the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.OpSCF or placebo will be adm...

Active, not recruiting
Atopic Dermatitis
Biological: Placebo
Biological: OpSCF

Phase 2

Opsidio

Rolling Meadows, Illinois, United States of America and 21 other locations

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

West Dundee, Illinois, United States and 41 other locations

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

Phase 3

AbbVie
AbbVie

Chicago, Illinois, United States and 179 other locations

Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 year...

Enrolling
Atopic Dermatitis
Sleep Disturbance
Drug: Dupilumab

Phase 4

Northwestern University
Northwestern University

Chicago, Illinois, United States

This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).

Active, not recruiting
Atopic Dermatitis Eczema
Drug: Placebo
Drug: ANB032

Phase 2

AnaptysBio
AnaptysBio

Flossmoor, Illinois, United States and 79 other locations

The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...

Active, not recruiting
Atopic Dermatitis
Drug: Dupilumab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Chicago, Illinois, United States and 83 other locations

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...

Enrolling
Eczema
Atopic Dermatitis
Drug: Placebo
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

Chicago, Illinois, United States and 97 other locations

This is a Phase 2, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S....

Begins enrollment in 1 month
Atopic Dermatitis
Drug: Placebo (Vehicle) Topical Gel
Drug: Fluocinonide Ointment

Phase 2

National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)

Chicago, Illinois, United States and 9 other locations

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with mode...

Invitation-only
Eczema
Atopic Dermatitis
Drug: Placebo
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

Chicago, Illinois, United States and 95 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems